Improved survival and leukocyte reconstitution without detrimental effects on engraftment in murine recipients of human recombinant granulocyte colony-stimulating factor after transplantation of T-cell-depleted histoincompatible bone marrow.
In vivo administration of human recombinant granulocyte colony-stimulating factor (rG-CSF) was evaluated for effects on survival, hematologic recovery, and engraftment in an allogeneic murine bone marrow transplantation (BMT) model involving T-cell depletion. Post-BMT recipients of continuous subcutaneous infusions of rG-CSF (n = 62) for 14 days had a significant survival advantage compared with post-BMT controls (n = 60) that received phosphate-buffered saline (PBS) infusions. Moreover, recipients of rG-CSF had significantly increased numbers of circulating leukocytes on days 7 and 14 post-BMT. Engraftment was not adversely affected. Administration of rG-CSF after transplantation of T-cell-depleted histoincompatible bone marrow benefits survival and leukocyte recovery without compromising engraftment.
Blazar
B R
BR
Department of Pediatrics, University of Minnesota Hospital and Clinic, Minneapolis.
Widmer
M B
MB
Cosman
D
D
Sassenfeld
H M
HM
Vallera
D A
DA
D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000473:pathology*; D003115:Colony-Stimulating Factors / Q000008:administration & dosage*; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor; D006410:Hematopoiesis / Q000187:drug effects; D006648:Histocompatibility; D007279:Injections, Subcutaneous; D007962:Leukocytes / Q000502:physiology*; D051379:Mice; D008815:Mice, Inbred Strains; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology
D003115:Colony-Stimulating Factors; D016179:Granulocyte Colony-Stimulating Factor